Match FDA cancer drugs to a tumor gene change
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 12 or older (some medicines may only be for patients 18+).
- Your cancer is advanced (locally advanced or metastatic) and not responding to standard treatment, or there’s no standard option.
- Your body can handle treatment (good baseline health score: ECOG 0–2).
- Your blood and organ tests are within limits (including certain white blood cells, hemoglobin, platelets, liver, and kidney function).
- Your cancer can be measured on scans or exam (not just tumor markers, and not “bone-only” without a measurable target).
- You have tumor testing done (a gene test or protein test/IHC) in an approved lab showing a match to an FDA targeted drug in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.